

Celeste M. Brecht (SBN 238604)  
Caroline D. Murray (SBN 301754)  
Ramanda R. Luper (SBN 313606)  
JONES DAY  
555 South Flower Street  
Floor 50  
Los Angeles, California 90071.2452  
Telephone: +1.213.489.3939  
Facsimile: +1.213.243.2539  
Email: cbrecht@jonesday.com  
carolinemurray@jonesday.com  
rluper@jonesday.com

*Attorneys for Defendant*  
ABBOTT LABORATORIES

**UNITED STATES DISTRICT COURT**  
**EASTERN DISTRICT OF CALIFORNIA**

MARGURITE PARIANI, on her own behalf  
and on behalf of her minor child E.P.,

*Plaintiffs,*

v.

MEAD JOHNSON & COMPANY, LLC,  
MEAD JOHNSON NUTRITION COMPANY,  
ABBOTT LABORATORIES, NORTHBAY  
HEALTHCARE GROUP, D/B/A  
NORTHBAY MEDICAL CENTER, and  
DOES 1-10, inclusive,

*Defendants.*

Case No. 22-at-424

**NOTICE OF REMOVAL AND  
REMOVAL OF ACTION UNDER 28  
U.S.C. § 1441 BY DEFENDANT  
ABBOTT LABORATORIES**

Complaint Filed: March 25, 2022  
Action Removed: April 27, 2022  
Trial Date: None Set

1           **TO THE CLERK OF THE ABOVE-ENTITLED COURT:**

2           **PLEASE TAKE NOTICE THAT** pursuant to 28 U.S.C. §§ 1332, 1441, and 1446,  
3 Defendant Abbott Laboratories (“Abbott”) gives notice that the above-captioned action pending in  
4 the Superior Court of the State of California, County of Solano, is hereby removed to the United  
5 States District Court for the Eastern District of California. This Court has original jurisdiction  
6 under 28 U.S.C. §§ 1332 and 1441 *et seq.* In support of this removal, Abbott further states as  
7 follows:

8           1. This is a civil action filed on or about March 25, 2022, by Plaintiff Margurite  
9 Pariani (“Plaintiff”) in the Superior Court of the State of California, Solano County, entitled  
10 *Margurite Pariani v. Mead Johnson & Company, LLC, et al*, bearing Case Number FCS057968.  
11 A true and correct copy of Plaintiff’s Complaint is attached to the Declaration of Celeste M.  
12 Brecht (“Brecht Decl.”) as **Exhibit A**.

13           2. Plaintiff’s filing of this action follows more than 300 other individuals who have  
14 filed similar lawsuits across the country in recent months. These cases are about infants who  
15 were born too early—before 37 weeks of gestation—and developed necrotizing enterocolitis  
16 (“NEC”), an umbrella term for a disease of the gastrointestinal tract that occurs in premature  
17 infants. NEC’s causes are both complex and multifactorial, meaning that it has many known  
18 contributing factors. Among these many risk factors, there are only two reliable prognostic  
19 parameters: gestational age and birth weight. The younger the infant’s gestational age and the  
20 less an infant weighs, the greater the risk that the infant will develop NEC.

21           3. These cases target a series of specialized formula and fortifier nutrition products  
22 that contain cow’s milk protein. These products are designed and sold specifically for premature  
23 infants who suffer from a host of medical issues relating to low birthweight and  
24 underdevelopment, regardless of what nutrition is administered.

25           4. Infants who are born prematurely, at a low birth weight, and are small for their  
26 gestational age have underdeveloped or maldeveloped gastrointestinal systems that are simply not  
27 prepared to receive nutrition outside the womb. As a result, highly specialized medical  
28 professionals must make sophisticated judgments about the substance, quantity, timing, and

1 method of administration when providing nutrition to these fragile infants. A team of NICU  
2 specialists continuously monitor premature infants for early signs of NEC (among the many other  
3 things that can go wrong). They do so regardless of how nutrition is administered, and regardless  
4 of whether it consists of the mother's own milk, human donor milk, specialized formula or  
5 fortifier, or a combination. Each of these lawsuits alleges that the use of Abbott and/or Mead  
6 Johnson's specialized nutrition products caused an infant's NEC because the products contain  
7 cow's milk protein. The evidence will show that there is no basis for these allegations. These  
8 products are safe and save lives. Without them, many more infants would die or suffer serious  
9 setbacks.

10         5.       Like those other actions, Plaintiff asserts product liability claims arising from the  
11 administration of Abbott's and/or Mead Johnson's specialized preterm infant formula and/or  
12 human milk fortifiers, which Plaintiff alleges caused her minor child E.P., who was born  
13 premature, to develop NEC. Plaintiff asserts the following causes of action ("COAs") against  
14 Abbott and Defendants Mead Johnson & Company, LLC and Mead Johnson Nutrition Company  
15 (together, "Mead Johnson"): (1) Strict Products Liability for Design Defect; (2) Strict Products  
16 Liability for Failure to Warn; (3) Negligence; (4) Intentional Misrepresentation; and (5) Negligent  
17 Misrepresentation.

18         6.       Unlike most of the lawsuits that preceded this one, however, Plaintiff also asserts  
19 *one* cause of action for Negligent Failure to Warn (Sixth COA) against Defendant Northbay  
20 Healthcare Group D/B/A Northbay Medical Center ("Northbay Healthcare"), the hospital at  
21 which Plaintiff's daughter E.P. was allegedly treated and where her physicians selected the  
22 preterm formula product at issue.

23         7.       This case is properly removed to this Court pursuant to 28 U.S.C. § 1441 because  
24 Abbott has satisfied the procedural requirements for removal and this Court has subject matter  
25 pursuant to 28 U.S.C. § 1332.

26         8.       As explained in detail below, Plaintiff improperly joined Defendant Northbay  
27 Healthcare in their claims asserted against Abbott and Mead Johnson.  
28

1           9.       Nearly all of the hundreds of plaintiffs who have filed similar product liability  
2 cases relating to specialized infant formula and fortifier products have asserted claims against the  
3 manufacturers alone—not any hospitals or medical providers—and there are sound reasons for  
4 this. Indeed, the California residents who filed in Illinois state court and who are likewise  
5 represented by Plaintiff’s counsel did not include any claims against the hospitals or medical  
6 providers.<sup>1</sup>

7           10.       The United States Judicial Panel for Multidistrict Litigation (“JPML”) recently  
8 established a Multi-District Litigation (“MDL”) for such claims against Abbott and Mead Johnson.  
9 *See In re Preterm Infant Nutrition Prods. Liab. Litig.*, MDL No. 3026, Order, Dkt. No. 119 (Apr.  
10 8, 2022) (hereinafter, the “Preterm Infant Nutritional Products MDL”). The Illinois Supreme  
11 Court recently declined, without prejudice, Abbott’s Rule 384 motion to consolidate the  
12 proceedings brought in Illinois state court (the “Illinois Litigation”).<sup>2</sup> More than a dozen law  
13 firms represent the plaintiffs across the country, some of which are leading the MDL and Illinois  
14 Litigation. By contrast, Plaintiff’s counsel here has filed cases in other jurisdictions, but have not  
15 gained a leadership position in those other proceedings.

16           11.       In an apparent attempt to secure a leadership role somewhere in this nationwide  
17 litigation, Plaintiff’s counsel is now attempting to assert claims against Northbay Healthcare to  
18 prevent removal and transfer to the Preterm Infant Nutrition Products MDL. In the last 42 days,  
19 Plaintiff’s counsel has filed at least 9 lawsuits in California on behalf of 25 plaintiffs, and 29  
20 lawsuits in Pennsylvania on behalf of 29 plaintiffs. In all of these lawsuits, Plaintiff’s counsel has  
21 named the manufacturers and ***also the hospitals*** in which the premature infants were born and/or  
22 treated as defendants. Indeed, had these cases been filed against only the product manufacturers  
23 (like the others), they would be readily removed and transferred to the MDL—where Plaintiff’s  
24 counsel has no leadership role. This gamesmanship should not be tolerated.

25  
26 <sup>1</sup> Plaintiff’s counsel’s decision to exclude local hospitals from those cases, and the demonstrated  
27 ability of those suits to proceed without them, undermines any anticipated argument that they are  
28 necessary or indispensable parties.

<sup>2</sup> Thirty-five of these cases are subject to pending personal jurisdiction, venue, and forum *non  
conveniens* motions brought by Abbott and/or Mead Johnson.

12. Having removed this action, Abbott shall promptly request that the JPML transfer this action to the Preterm Infant Nutrition Products MDL pursuant to the “tag-along” procedure contained in the JPML Rules. In addition, Abbott contemporaneously seeks a stay of these proceedings in the interest of judicial efficiency and consistency so that the MDL can address future motions, if any.

**I. ABBOTT HAS SATISFIED THE PROCEDURAL REQUIREMENTS FOR REMOVAL**

13. Pursuant to 28 U.S.C. § 1446(a), Abbott attaches to this Notice of Removal a true and correct copy of all process, pleadings, and orders filed in the state court action. *See* Brecht Decl., **Exs. A-G**. Abbott further attaches a true and correct copy of the state court docket. *See* Brecht Decl., **Ex. H**.

14. Promptly following the filing of this Notice of Removal, written notice of the removal of this action will be served on all parties’ counsel, as required by 28 U.S.C. § 1446(d).

15. A true and correct copy of this Notice of Removal will also be promptly filed with the Superior Court of the State of California, Solano County, pursuant to 28 U.S.C. § 1446(d).

16. Venue for this action is proper in this Court under 28 U.S.C. § 1441(a) because Solano County is located within the United States District Court for the Eastern District of California (28 U.S.C. § 84(b)). Accordingly, the Eastern District of California is the “district and division embracing the place where such action is pending.” 28 U.S.C. § 1441(a).

17. Plaintiff filed this action in the aforementioned state court on or about March 25, 2022. Abbott’s registered agent was served with the Complaint via process server on or about March 29, 2022. Mead Johnson, who was served on or about March 29, 2022, has consented to removal. No consent for removal from Northbay Healthcare is required because, as set forth below, it was not properly joined. *See* 28 U.S.C. § 1446(b)(2)(A) (providing that only those defendants who have been “properly joined and served” must consent).

18. This Notice of Removal is timely pursuant to 28 U.S.C. § 1446 because it is filed within thirty (30) days of formal service upon Abbott.

19. No previous application has been made for the relief requested herein.

**II. REMOVAL IS PROPER BECAUSE THIS COURT HAS ORIGINAL JURISDICTION PURSUANT TO 28 U.S.C. § 1332(A)**

20. This Court has diversity jurisdiction pursuant to 28 U.S.C. § 1332(a) because this is a civil action in which the *properly* joined parties are citizens of different states and the amount in controversy exceeds the sum of \$75,000 for each plaintiff's claims, exclusive of costs and interest.

**A. The Amount In Controversy Requirement Is Satisfied**

21. It is evident from the Complaint that the amount in controversy exceeds \$75,000, exclusive of interests and costs.

22. Under 28 U.S.C. § 1446(c)(2), "[i]f removal of a civil action is sought on the basis of the jurisdiction conferred by section 1332(a), the sum demanded in good faith in the initial pleading shall be deemed to be the amount in controversy, except that—

- (A) the notice of removal may assert the amount in controversy if the initial pleading seeks. . . (ii) a money judgment, but the State practice either does not permit demand for a specific sum or permits recovery of damages in excess of the amount demanded," and
- (B) removal of the action is proper on the basis of an amount in controversy asserted under subparagraph (A) if the district court finds, by the preponderance of the evidence, that the amount in controversy exceeds the amount specified in section 1332(a).

28 U.S.C. § 1446(c)(2)(A)-(B); Federal Courts Jurisdiction and Venue Clarification Act of 2011, Pub. L. 112-63, Dec. 7, 2011. When plaintiffs do not allege a specific amount of damages in the complaint, the defendant must demonstrate the likelihood that plaintiffs' claims each exceed \$75,000, exclusive of interest and costs. *See Valdez v. Allstate Ins. Co.*, 372 F.3d 1115 (9th Cir. 2004); *Gaus v. Miles, Inc.*, 980 F.2d 564, 566 (9th Cir. 1992). A removing defendant need only show that the amount in controversy "more likely than not" exceeds the jurisdictional amount of \$75,000. *Sanchez v. Monumental Life Ins. Co.*, 102 F.3d 398, 404 (9th Cir. 1996); *Singer v. State Farm Mut. Auto. Ins. Co.*, 116 F.3d 373, 376 (9th Cir. 1997). When the amount in controversy is not specified in the complaint, the court may consider the facts alleged in the complaint as well as in the notice of removal. *See Simmons v. PCR Tech.*, 209 F. Supp. 2d 1029, 1031 (N.D. Cal. 2002); 28 U.S.C. § 1446(c)(2).

23. Plaintiff's Complaint does not allege a specific amount in controversy. Nevertheless, it is evident that the amount in controversy is satisfied. Plaintiff seeks general and compensatory damages, including medical damages, lost earning capacity, and pain and suffering.<sup>3</sup> See, e.g., Compl. ¶¶ 9, 13, 71-72, 80, 89, 98-99, 108-109; *id.*, Prayer for Relief, ¶¶ 124-129. Where, as here, a plaintiff alleges serious bodily injury in the context of a product liability action, California federal courts have found that the amount-in-controversy requirement is satisfied. See, e.g., *Bryant v. Apotex, Inc.*, No. 1:12-CV-01377-LJO-JLT, 2012 WL 5933042, at \*4 (E.D. Cal. Nov. 27, 2012) (holding that amount-in-controversy requirement was met in products liability action, although "complaint [did] not set forth a specific amount of damages," because plaintiff sought "compensatory damages for injuries and severe pain lasting six months, severe emotional distress, and punitive damages" after allegedly enduring tightening and inflammation of the esophagus); *Campbell v. Bridgestone/Firestone, Inc.*, No. 1:05-CV-01499-FVS-DLB, 2006 WL 707291, at \*2-3 (E.D. Cal. Mar. 17, 2006) (holding that amount in controversy exceeded \$75,000, and denying motion to remand, in products liability case where plaintiff sought compensatory damages, including lost wages and loss of earning capacity, medical expenses, and general damages, after suffering head trauma and broken bones).

24. Given that Plaintiff's claims for economic and non-economic damages are related to injuries allegedly resulting from the administration of preterm formula products and/or fortifiers, and Plaintiff alleges extensive injury, medical expenses, pain and suffering, and emotional distress, it is evident that the damages sought by Plaintiff exceeds \$75,000. See, e.g., Compl. ¶¶ 9, 13, 71-72, 80, 89, 98-99, 108-109.

**B. Complete Diversity of Citizenship Exists Between the Properly Joined Parties**

25. This case is between "citizens of different States and in which citizens or subjects of a foreign state are additional parties." 28 U.S.C. § 1332(a)(1). As explained below, all properly joined and served defendants are diverse from Plaintiff.

<sup>3</sup> Abbott does not concede that Plaintiff would be entitled to any of the relief sought in the Complaint.

1                   **1. Plaintiff Is A Citizen of California**

2           26. Upon information and belief, at all times relevant hereto, Plaintiff was a resident  
3 and citizen of California. Compl. ¶ 3.

4                   **2. Abbott Is A Not A Citizen of California**

5           27. Abbott is now, and was at the time Plaintiff commenced this action, a corporation  
6 organized under the laws of the State of Illinois with its corporate headquarters in Lake County,  
7 Illinois. It is therefore a resident of Illinois. Compl. ¶ 5.

8                   **3. Mead Johnson Is Not A Citizen of California**

9           28. Mead Johnson Nutritional Company is a wholly-owned subsidiary of Reckitt  
10 Benckiser PLC and is now, and was at the time Plaintiff commenced this action, a corporation  
11 organized under the laws of the State of Delaware, with its principal place of business in the State  
12 of Indiana. It is thus a resident of those two states. Compl. ¶ 4.

13           29. Mead Johnson & Company, LLC is a limited liability company whose sole  
14 member is Mead Johnson Nutritional Company, and is therefore a resident of the States of  
15 Delaware and Indiana. *Id.*

16                   **4. Northbay Healthcare's Citizenship Must Be Disregarded**

17           30. Northbay Healthcare is a corporation created under the laws of the State of  
18 California. Compl. ¶ 6.

19           31. While Northbay Healthcare is a citizen of California, it was not “properly joined”  
20 for the reasons set forth below. *See* U.S.C. § 1441(b). Thus, Northbay Healthcare’s citizenship  
21 must be disregarded for the purposes of determining the propriety of removal.

22                   **5. The Citizenship Of The Doe Defendants Shall Not Be Considered**

23           32. The citizenship of the Doe Defendants shall not be considered for the purposes of  
24 determining diversity jurisdiction, as these are fictional defendants. *See* 28 U.S.C. § 1441(b) (“In  
25 determining whether a civil action is removable on the basis of the jurisdiction under section  
26 1332(a) of this title, the citizenship of defendants sued under fictitious names shall be  
27 disregarded.”).



**B. Northbay Healthcare Was Fraudulently Joined And Its Citizenship Must Be Disregarded**

33. The presence of Northbay Healthcare in this case does not defeat diversity jurisdiction, and does not prevent removal, because Northbay Healthcare was fraudulently joined.

34. For this Court to exercise diversity jurisdiction over the case, all parties must be diverse. *See* 28 U.S.C. § 1446(b) (providing the procedure for removal based on diversity of citizenship); 28 U.S.C. § 1332(a) (granting federal courts original jurisdiction over all actions where the matter in controversy exceeds the sum or value of \$75,000, exclusive of interests and costs, and is between citizens of different States). Plaintiff has attempted to take advantage of this procedural requirement by naming Northbay Healthcare—a California citizen—so that “at first blush it must be said that there [is] no diversity.” *Ritchey v. Upjohn Drug Co.*, 139 F.3d 1313, 1318 (9th Cir. 1998).

35. As *Ritchey* suggests, however, courts have grown wise to this practice. In *Ritchey*, plaintiff named two non-diverse defendants, a physician and Stanford Health Services, in a product liability suit even though his claims against those providers were barred by the statute of limitations. *Ritchey*, 139 F.3d at 1320. Upjohn Drug Company, the manufacturer of the drug that plaintiff claimed caused his injuries, removed the case despite the presence of the two California defendants. *Id.* at 1315. The district court denied plaintiff’s motion to remand. *Id.* The Ninth Circuit affirmed, holding that “fraudulently joined defendants will not defeat removal on diversity grounds.” *Id.* The court further explained that “fraudulent joinder” is a term of art: “If the plaintiff fails to state a cause of action against a resident defendant, and the failure is obvious according the settled rules of the state, the joinder of the resident defendant is fraudulent.” *Id.* at 1318.

36. The Ninth Circuit also explained that courts must go beyond the pleadings to determine the existence of federal jurisdiction. “Where fraudulent joinder is an issue,” “[t]he defendant seeking removal to the federal court is entitled to present the facts showing the joinder to be fraudulent.” *Id.*

37. Although “the test for fraudulent joinder and for failure to state a claim under Rule 12(b)(6) are not equivalent,” they are similar in that they “[b]oth require some assessment of the plaintiff’s lawsuit” and of whether “the complaint states a cause of action.” *Grancare, LLC v. Thrower by & through Mills*, 889 F.3d 543, 549–50 (9th Cir. 2018); *see Isaacs v. Broido*, 358 Fed. App’x. 874, 877 (9th Cir. 2009) (holding that “the Rule 12(b)(6) inquiry and the fraudulent joinder inquiry substantially overlap on the issue of failure to state a claim” and that district court could have “dismissed the fraudulently joined defendants on its own motion.”).

38. Ninth Circuit courts have repeatedly held that a defendant is fraudulently joined—and its presence in a lawsuit is therefore disregarded for removal purposes—when a plaintiff would be unable establish the elements of the claim or claims they have brought against the defendant. *See, e.g., Morris v. Princess Cruises, Inc.*, 236 F.3d 1061, 1067 (9th Cir. 2001) (affirming district court’s application of the fraudulent joinder doctrine where plaintiff could not show that sales statement was more than puffery and thus “could not possibly prevail on her negligent misrepresentation claim” against the non-diverse defendant); *United Computer Sys., Inc. v. AT&T Corp.*, 298 F.3d 756, 761 (9th Cir. 2002) (affirming district court’s application of the fraudulent joinder doctrine where the non-diverse defendant was not a signatory to any of the contracts that plaintiff alleged had been breached and so could not be liable); *TPS Utilicom Servs., Inc. v. AT&T Corp.*, 223 F. Supp. 2d 1089, 1100-01 (C.D. Cal. 2002) (finding that non-diverse defendants were fraudulently joined after holding that “[t]he factual allegations in the complaint against the resident defendants are wholly inadequate under California law to state a claim.”); *see also Great Plans Trust Co. v. Morgan Stanley Dean Witter & Co.*, 313 F.3d 305, 312 (5th Cir. 2002) (affirming district court’s finding of fraudulent joinder and recognizing that a “reasonable” basis to predict that a plaintiff could prevail on his or her claims against the in-state defendants requires more than a “theoretical” basis).

39. Thus, to state a proper claim against Northbay Healthcare, Plaintiff must allege “enough facts to state a claim to relief that is plausible on its face” and allow the court to draw the reasonable inference that the defendant is liable for the misconduct alleged. *Bell Atlantic Corp. v. Twombly*, 550 U.S. 544, 570 (2007). Legal conclusions and threadbare recitals of elements,

supported by mere conclusion, simply do not suffice. *Ashcroft v. Iqbal*, 556 U.S. 662, 678 (2009). This Court is “not bound to accept as true a legal conclusion couched as a factual allegation.” *Twombly*, 550 U.S. at 555. Rather, Federal Rule of Civil Procedure 8 “contemplate[s] the statement of circumstances, occurrences, and events in support of the claim presented.” *Id.* at 556. As a consequence, pleadings—such as Plaintiff’s Complaint here—that fail to set forth factual allegations to support asserted legal conclusions against non-diverse defendants should be deemed fraudulent and dismissed. *Id.* at 555; *see also Iqbal*, 556 U.S. at 678-79 (“Rule 8 . . . does not unlock the doors of discovery for a plaintiff armed with nothing more than conclusions.”).

**6. The Sixth COA And Only Cause of Action Brought  
Against Northbay Healthcare Alone Fails As A Matter of Law.**

40. Plaintiff alleges only one cause of action—negligent failure to warn—against Northbay Healthcare alone. *See* Compl. ¶¶ 110-123. However, the Sixth COA readily fails as a matter of law.

41. In California, negligent failure to warn claims apply only to a manufacturer or distributor of the product at issue. *See Anderson v. Owens-Corning Fiberglas Corp.*, 53 Cal.3d 987, 1002 (1991) (“Negligence law in a failure-to-warn case requires a plaintiff to prove that a *manufacturer or distributor* did not warn of a particular risk for reasons which fell below the acceptable standard of care, *i.e.*, what a reasonably prudent manufacturer would have known and warned about.” (emphasis added)); Judicial Council of California, Civil Jury Instruction No. 1222. Negligence – Manufacturer or Supplier – Duty to Warn – Essential Factual Elements (“To establish this claim, [Plaintiff] must prove all of the following: . . . 1. That [Northbay Healthcare] manufactured/distributed/sold the [specialized infant formula and fortifier products].”)

42. Presumably for that reason, Plaintiff alleges that Northbay Healthcare operates as a distributor or supplier of the specialized infant formula products at issue such that it owed a duty to warn Plaintiff of risks associated with the products. *See* Compl. ¶ 111 (“NorthBay [Healthcare], as [a] purchaser, supplier, and/or distributor of the products at issue in this

litigation, owed a duty to the consuming public in general, and Plaintiff in particular. . . .”). Yet, under California law, hospitals are *not* sellers or distributors of products or other goods used in the course of providing medical services. Instead, the business of a hospital is to provide medical services to patients. See *Silverhart v. Mount Zion Hosp.*, 98 Cal. Rptr. 187, 191 (Cal. App. 1971) (holding hospital not liable for allegedly defective surgical needle because “a hospital furnishing a [product] as part of the medical services it provides is not a seller engaged in the business of selling [products]”); *San Diego Hosp. Ass’n. v. Superior Court*, 35 Cal. Rptr. 2d 489, 493 (Cal. App. 1994) (holding hospital not liable for injuries caused to physician by allegedly defective laser because “[t]he hospital is not in the business of selling or even leasing, bailing or licensing equipment to the physician. It is in the business of providing medical services to its patients. . . . The fact the hospital provides equipment for the physician’s use is incidental to the overriding purpose of providing medical services”); *Hector v. Cedars-Sinai Med. Ctr.*, 225 Cal. Rptr. 595, 599 (Cal. App. 1986) (holding hospital not liable for personal injury resulting from defective pacemaker because it “is not ‘engaged in the business of distributing [products] to the public’ . . . and does not play ‘an integral and vital part in the overall production or marketing’ of [products]”); *Shepard v. Alexian Bros. Hosp.*, 109 Cal. Rptr. 132, 135 (Cal. App. 1973) (holding hospital not liable for personal injury where plaintiff contracted hepatitis from blood transfusion because “[t]he patient who enters a hospital goes there not to buy [products], but to obtain a course of treatment”).

43. Indeed, California courts have applied this reasoning to every aspect of the care that hospitals provide. See *Pierson v. Sharp Mem’l Hosp., Inc.*, 264 Cal. Rptr. 673, 676 (Cal. App. 1989) (finding that hospital could not even be held liable for allegedly defective carpet in patient’s room because “hospitals a[re] providers of professional medical services rather than producers or marketers of products” and “[a] patient’s room is part of the specialized facilities enabling the patient to receive 24-hour nursing care and immediate access to other vital medical services.”).

44. Plaintiff admits—indeed, she cannot reasonably dispute—that the specialized infant nutrition products at issue here were administered by doctors and medical staff as part of

1 the medical services that Northbay Healthcare provided to Plaintiff's daughter as a premature  
2 infant. Compl. ¶ 113 (alleging that the infants received the products at the direction of Northbay  
3 Healthcare's healthcare professionals and medical staff in the course of treating the infants).  
4 Accordingly, Plaintiff cannot show that Northbay Healthcare was either a distributor or supplier  
5 of premature infant formula or fortifier products; instead, Northbay Healthcare was purely a  
6 provider of medical services.

7 45. Because Northbay Healthcare cannot be held liable under Plaintiff's negligent  
8 failure to warn theory, Plaintiff's Sixth COA—and only claim against Northbay Healthcare—fails  
9 as a matter of law.

10 46. Against this existing backdrop, and because Plaintiff cannot state a viable claim  
11 against Northbay Healthcare, it is evident that Plaintiff joined Northbay Healthcare only to  
12 attempt to destroy diversity jurisdiction. Accordingly, the Court should find that removal under  
13 diversity jurisdiction is proper because Northbay Healthcare has been fraudulently joined and,  
14 therefore, its citizenship must be disregarded.

15 **III. CONCLUSION**

16 53. There is complete diversity amongst the properly joined parties, and this Notice of  
17 Removal is appropriate pursuant to 28 U.S.C. § 1441(b).

18 54. Based on the foregoing, the state court action may be removed to this Court in  
19 accordance with the provisions of 28 U.S.C. §§ 1332 and 1441 *et. seq.* because this is a civil  
20 action pending within the jurisdiction of this Court; this action is between citizens of different  
21 states; and the amount in controversy exceeds \$75,000, exclusive of interest and costs.

22 55. No admission of fact, law, or liability is intended by this Notice of Removal, and  
23 the Abbott expressly reserve all defenses, counterclaims, and motions otherwise available to it.

24 //

25 //

1           WHEREFORE, Abbott removes this action, now pending in the Superior Court of the  
2 State of California, Solano County, Case No. FCS057968, to this Court.

3 Dated: April 27, 2022

JONES DAY

4  
5 By: /s/ Celeste M. Brecht

6 Celeste M. Brecht  
7 Caroline D. Murray  
8 Ramanda R. Luper

9 *Attorneys for Defendant*  
10 ABBOTT LABORATORIES  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28